

جمعية الرعاية الصحية HEALTH CARE SOCIETY

ANNUAL REPORT

LEBANON 2023

CONTENTS

- 1 NOTE FROM THE EXECUTIVE DIRECTOR
- 2 MISSION, VALUES, AND OBJECTIVES
- 3 DIALYSIS PROGRAM
- 4 SURGERIES AND HOSPITALIZATIONS PROGRAM
- 5 THALASSEMIA AND SICKLE CELL DISEASE PROGRAM
- 6 FINANCIAL REPORT



BOARD OF DIRECTORS

DR. MIGUEL ABBOUD

President

MRS. WAFA AL YASSIR

Vice President

MR. KASSEM AINA

Treasurer

MS. SAWSAN MASRI

Secretary

DR. FATIMA ABU SALEM

Member

DR. MIRA MERASHLI

Member

DR. MONA OSMAN

Member

STAFF MEMBERS

DR. HEBAH EL-RAYESS

Executive Director

MR. MOHAMMAD EL SADEK

Accountant

A NOTE FROM THE EXECUTIVE DIRECTOR

A Note from the Executive Director

Dear Friends of HCS,

One of the greatest privileges in life is the opportunity to care for those less fortunate. From its early days supporting a handful of beneficiaries with kidney failure at Hamshari Hospital in Saida to its current program with 2 locations and 150 beneficiaries, Healthcare Society has saved more lives over a longer period of time than any other civil society organization in Lebanon. HCS' programs have persisted despite all odds through explosions, civil unrest, a pandemic, and the country's economic collapse. This is largely a testament to our donors and their astute recognition and appreciation of the essential services HCS provides.

Despite recent changes in legislation by the Lebanese government giving Palestinians permission to work in domains from which they were previously excluded, the Palestinian refugee community continues to struggle with poverty and statelessness. This has been magnified by an overwhelming sense of grief that has overtaken the community since the onset of the brutal Israeli military campaign against Gaza and Lebanon in October. The defunding of UNRWA by western nations will have significant effects on Palestinian refugees throughout the region, but most significantly in Lebanon. More than 90% of Palestinians in Lebanon have no form of healthcare coverage. As such, if the proposed cuts in UNRWA lead to the cessation of their operations in Lebanon, HCS will be one of the only organizations providing financial support for secondary and tertiary medical care of Palestinians.

LOOKING AHEAD

2024 will promise upgrades to the dialysis machines and dialysis chairs in the Hamshari Hospital Dialysis Center. We will also conduct a study to assess the mental health needs of Palestinian refugees in Lebanon living with kidney failure. The results will be used to develop effective interventions to improve their mental health and, as a result, overall health outcomes. Additionally, we plan to develop educational campaigns emphasizing the prevention of kidney failure. For our surgeries and hospitalizations project, we hope to expand the geographical scope of the project by cooperating with more hospitals throughout the country.

We thank you all for your continued support of our essential programs.

Dr. Hebah El-Rayess Executive Director

MISSION, VALUES, AND OBJECTIVES

Mission, Values, and Objectives



OUR MISSION

>> To provide health security to Palestinian refugees in Lebanon.



OUR VALUES

HCS' ethical framework is grounded in the following values: commitment, solidarity, dignity, and tolerance.





- >> To contribute to the costs of quality secondary and tertiary medical care.
- >> To support emergency cases that are not covered by any other institution.
- >> To support those suffering from chronic diseases such as kidney failure and inherited blood disease.
- >> To engage in evidence-based advocacy promoting quality health care with dignity.
- >> To provide health education and awareness.
- >> To provide medications and medical supplies according to needs.

DIALYSIS PROGRAM



with kidney failure who rely on this lifesaving project.

Dialysis Program

In 2023, HCS continued its 25-year cooperation with Taawon and the Palestinian Red Crescent Society for the dialysis programs in Saida and Tripoli. Demand for dialysis services continues to rise among the Palestinian refugee population in Lebanon. In 2023, HCS provided a record number of dialysis sessions, reaching over 18,000. The number of beneficiaries we support also continues to grow, rising to 150 people

The increasing number of patients and decreasing average age led us to investigate the cause of kidney failure among the Palestinian refugee population in Lebanon. The most common causes appear to be high blood pressure and diabetes.

Fortunately, both conditions are preventable. As such, we hope to develop educational campaigns targeting the Palestinian communities to help them better understand how to prevent these chronic diseases and the importance of early detection and treatment. We hope to collaborate with UNRWA and other local actors to conduct these educational campaigns.

This year we received a generous donation of 4,200 doses of erythropoietin from the Bashir Alami Family Trust. This is an essential medication for the treatment of anemia, which is common among people with kidney failure. Erythropoietin stimulates the production of red blood cells and reduces the need for blood transfusions.

DIALYSIS PROGRAM 2023 STATISTICS			
	HAMSHARI	SAFAD	TOTAL
Number of beneficiaries	107	43	150
Average age	58	52	57
% Female	43	42	43
Number of dialysis sessions	12,358	6,011	18,369

SURGERIES & HOSPITALIZATIONS PROGRAM

Surgeries & Hospitalizations Program

OVERVIEW

The need for support of surgeries and hospitalizations continues to rise among the Palestinian refugee population in Lebanon. In 2023 provided financial support to 57 adults and children inn need thanks our donors NORWAC and Taawon. Support was provided for a wide variety of interventions - from cochlear implants to emergency cardiac surgery. Beneficiaries' ages ranged from 1 year old to 85 years old. The average age was forty-seven.

HCS cooperated with hospitals across the country to ensure that all Palestinian refugeess could access the program. We currently have formal agreements with 8 hospitals throughout the country. Forty-five percent of beneficiaries in 2023 were from camps located in south Lebanon, including El Buss, Burj El Shemali, and Ein El Helweh.

COVERAGE FOR THE ELDERLY

HCS began the implementation of a special project developed by donor Taawon for elderly Palestinians (above age 65) in need of surgery or hospitaliation. The areas covered are Bekaa/Baalbak and north Lebanon. For this project we expanded the network of hospitals we cooperate with to include:

- Dar Al Amal Hospital in Baalbak
- Bekaa Hospital in Bekaa Valley
- Islamic Hospital in Tripoli



SURGERIES & HOSPITALIZATION	S		
TYPE OF INTERVENTION	MALE	FEMALE	TOTAL
Orthopedic surgery	6	11	17
Cardiac surgery	10	6	16
Cancer-related surgery	7	3	10
Hospitalization	2	6	8
General surgery	4	0	4
Eye and ear surgery	0	2	2
TOTAL	29	28	57

THALASSEMIA & SICKLE CELL DISEASE PROGRAM


Thalassemia & Sickle Cell Disease Program

The thalassemia and sickle cell program also continues to grow, with 124 adults and children enrolled. The program, funded by NORWAC and PCRF, provides access to a specialized sickle cell and thalassemia clinic at the American University of Beirut Medical Center. There, beneficiaries receive comprehensive care including genetic counseling - an important component of prevention.

The weekly transportation that HCS has provided since 2021 is now one of the most valued features of the project. Patients and caregivers from the south appreciate the comfort and convenience of the vehicle as it reduces the mental load associated with managing a chronic disease. A serendipitous benefit of the shared transport is the informal support groups that have developed among the beneficiaries during their journeys to AUBMC.

In 2023, we received a generous donation of 600 boxes of hydroxyurea (Cureaml) from Hikma Pharmaceutical. The donation was made possible by the efforts of the Bashir Alami Family Trust. This medication is essential in preventing sickle cell pain crises.





FINANCIAL REPORT

Financial Report

STATEMENT OF FINANCIAL POSITION

	<u>2023 (USD)</u>
ASSETS:	
Cash:	
- Fresh Money (Restricted for projects)	117,688.00
- Fresh Money (Nonrestricted)	121,430.51
- Non-Fresh Money	76,046.07
Accounts Receivable	415,538.00
Total Assets	730,702.58
Liabilities & Fund Balance	
Current Liabilities	
Promissory Notes	32,621.41
Hospital Bills	10,668.00
Deferred revenue	344,294.00
Total Current liabilities	387,583.41
Fund Balance at beginning of year	300,274.63
Surplus for the period	42,844.54
Ending Fund balance	343,119.17
Total Liabilities & Fund balance	730,702.58

FINANCIAL REPORT

STATEMENT OF ACTIVITIES

	(USD) 2023
Revenues, Gains, and other Support:	
Taawon (surgery)	29,300.00
Taawon (Kidney dialysis)	574,165.22
NORWAC	140,600.00
Palestinian Children relief Fund	9,076.41
Bashir Alami Fund	71,480.00
Individuals Donations	3,394.00
NGO's Staff Contributions	156.00
Other Revenue	2,606.26
Total Revenues, Gains and Other Support	830,777.89
Expenses:	
Program service:	
Hospitalizations and Surgeries	59,047.31
Thalassemia & Sickle Cell Program	50,190.88
Kidney Dialysis Centers- Hamshari & Safad Hospital	581,413.00
Total Program Service	690,651.19
Administrative and Support:	
Employees' Salaries & Auditing	57,260.00
Office equipment/ Supplies/ printing & Stationary	201.36
Employees medical Insurance	6,762.00
Office rental – services & generator fees	6,030.00
Transportation- fuel & automobile maintenance	1,225.02
Bank service charges	5,250.25
Website Upgrading	450.00
Miscellaneous/Utilities/Maintenance/Telephone/Internet	2,307.48
VAT	352.55
Total Administrative and support	79,838.66
Other Expenses:	·
Loss on change of bank exchange rate (15000/ 1 USD)	17,443.50
Total Expenses	787,933.35
Surplus	42,844.54

FINANCIAL REPORT

STATEMENT OF CASH FLOWS

	2023(\$)
CASH FLOWS FROM OPERATING ACTIVITIES	
Cash received from Welfare association	680,124.53
Cash received from NORWAC	140,600.00
Cash received from Bashir Alami Family Fund	71,480.00
Cash received from Individuals Donations	3,394.00
Cash received from Palestine Children's Relief Fund	9,076.41
Cash received from Contributions from NGO's Staff	156.00
Cash received from Other Income	2,606.26
Cash paid to Hospitalization Support	(59,047.31)
Cash paid for Thalassemia & Sickle Cell Treatment	(54,664.65)
Cash paid for medical aid from previous year	(103,949.59)
Cash paid for kidney dialysis centers-Hamshari & Safad	(636,175.40)
Administrative Expenses	(97,282.16)
Net decrease in cash	(43,681.91)
Cash and Cash equivalents at beginning of year	358,846.49
Cash and Cash equivalents at End of year	315,164.58